Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov;50(11):9529-9543.
doi: 10.1007/s11033-023-08749-y. Epub 2023 Sep 23.

Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities

Houman Isazadeh  1 , Farshid Oruji  2 , Shima Shabani  3 , Javad Behroozi  4 , Hadi Nasiri  1 , Alireza Isazadeh  1 , Morteza Akbari  5   6
Affiliations
Review

Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities

Houman Isazadeh et al. Mol Biol Rep. 2023 Nov.

Abstract

Advancements in the clinical applications of small interfering RNA (siRNA) in cancer therapy have opened up new possibilities for precision medicine. siRNAs, as powerful genetic tools, have shown potential in targeting and suppressing the expression of specific genes associated with cancer progression. Their effectiveness has been further enhanced by incorporating them into nanoparticles, which protect siRNAs from degradation and enable targeted delivery. However, despite these promising developments, several challenges persist in the clinical translation of siRNA-based cancer therapy. This comprehensive review explores the progress and challenges associated with the clinical applications of siRNA in cancer therapy. This review highlights the use of siRNA-loaded nanoparticles as an effective delivery system for optimizing siRNA efficacy in various types of carcinomas and the potential of siRNA-based therapy as a genetic approach to overcome limitations associated with conventional chemotherapeutic agents, including severe drug toxicities and organ damage. Moreover, it emphasizes on the key challenges, including off-target effects, enzymatic degradation of siRNAs in serum, low tumor localization, stability issues, and rapid clearance from circulation that need to be addressed for successful clinical development of siRNA-based cancer therapy. Despite these challenges, the review identifies significant avenues for advancing siRNA technology from the laboratory to clinical settings. The ongoing progress in siRNA-loaded nanoparticles for cancer treatment demonstrates potential antitumor activities and safety profiles. By understanding the current state of siRNA-based therapy and addressing the existing challenges, we aim to pave the way for translating siRNA technology into effective oncologic clinics as an improved treatment options for cancer patients.

Keywords: Cancer therapy; Nanoparticles; Precision medicine; Small interfering RNA.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mattiuzzi C, Lippi G (2019) Current cancer epidemiology. J Epidemiol global health 9(4):217 - DOI
    1. Rabiee F, Eghbalifard N, Fathi M, Rajabi H, Riazi SS (2023) Evaluation of the potential of the MicroRNAs to predict chemotherapy resistance in breast cancer patients: a systemic review with meta-analysis. Int J Sci Res Dent Med Sci 5(3):135–140.
    1. Kumar M, Eshwaraiah CB, KP A, Rudrappa SM (2023) Correlation of tumor-infiltrating lymphocytes with tumor staging and grading in breast carcinomas: a retrospective study. Int J Sci Res Dent Med Sci 5(1):16–20.
    1. Guo W, Chen W, Yu W, Huang W, Deng W (2013) Small interfering RNA-based molecular therapy of cancers. Chin J cancer 32(9):488 - PubMed - PMC - DOI
    1. Khan P, Siddiqui JA, Lakshmanan I, Ganti AK, Salgia R, Jain M, Batra SK, Nasser MW (2021) RNA-based therapies: a cog in the wheel of lung cancer defense. Mol Cancer 20(1):1–24 - DOI

Substances

LinkOut - more resources